Devasagayaraj Richard, Cavarocchi Nicholas C, Hirose Hitoshi
Department of Surgery, Thomas Jefferson University, Philadelphia, PA.
Perfusion. 2018 Jul;33(5):375-382. doi: 10.1177/0267659118755272. Epub 2018 Jan 23.
Patients who develop severe acute respiratory distress syndrome (ARDS) despite full medical management may require veno-venous extracorporeal membrane oxygenation (VV ECMO) to support respiratory function. Survival outcomes remain unclear in those who develop acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT) during VV ECMO for isolated severe respiratory failure in adult populations.
A retrospective chart review (2010-2016) of patients who underwent VV ECMO for ARDS was conducted with university institutional review board (IRB) approval. Patients supported by veno-arterial ECMO were excluded. AKI was defined by acute renal failure receiving CRRT and the outcomes of patients on VV ECMO were compared between the AKI and non-AKI groups.
We identified 54 ARDS patients supported by VV ECMO (mean ECMO days 12 ± 6.7) with 16 (30%) in the AKI group and 38 (70%) in the non-AKI group. No patient had previous renal failure and the serum creatinine was not significantly different between the two groups at the time of ECMO initiation. The AKI group showed a greater incidence of complications during ECMO, including liver failure (38% vs. 5%, p=0.002) and hemorrhage (94% vs. 45%, p=0.0008). ECMO survival of the AKI group (56% [9/16]) was inferior to the non-AKI group (87% [33/38], p=0.014).
Our study demonstrated that VV ECMO successfully manages patients with severe isolated lung injury. However, once patients develop AKI during VV ECMO, they are likely to further develop multi-organ dysfunction, including hepatic and hematological complications, leading to inferior survival.
尽管接受了全面的药物治疗,但仍发展为严重急性呼吸窘迫综合征(ARDS)的患者可能需要静脉-静脉体外膜肺氧合(VV ECMO)来支持呼吸功能。对于成年人群中因单纯严重呼吸衰竭在VV ECMO期间发生急性肾损伤(AKI)并需要持续肾脏替代治疗(CRRT)的患者,其生存结果仍不明确。
在大学机构审查委员会(IRB)批准下,对因ARDS接受VV ECMO治疗的患者进行了回顾性病历审查(2010 - 2016年)。排除接受静脉-动脉ECMO支持的患者。AKI定义为接受CRRT的急性肾衰竭,并比较AKI组和非AKI组接受VV ECMO治疗患者的结局。
我们确定了54例接受VV ECMO支持的ARDS患者(平均ECMO天数12±6.7天),其中AKI组16例(30%),非AKI组38例(70%)。所有患者既往均无肾衰竭,在开始ECMO时两组血清肌酐无显著差异。AKI组在ECMO期间并发症发生率更高,包括肝功能衰竭(38%对5%,p = 0.002)和出血(94%对45%,p = 0.0008)。AKI组的ECMO生存率(56% [9/16])低于非AKI组(87% [33/38],p = 0.014)。
我们的研究表明,VV ECMO成功治疗了严重单纯性肺损伤患者。然而,一旦患者在VV ECMO期间发生AKI,他们可能会进一步发展为多器官功能障碍,包括肝脏和血液学并发症,导致生存率降低。